2012
DOI: 10.3892/or.2012.1906
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The role of Wilms' tumor 1 (WT1) in breast cancer and the relationship between WT1 expression and clinicopathological factors, molecular subtypes and prognosis of breast cancer patients have not been clarified to date. We used publicly available microarray datasets of 266 early breast cancer patients to perform bioinformatics analysis on the relationship between WT1 mRNA expression and breast cancer. Results showed that WT1 mRNA expression was correla… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
16
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 23 publications
(16 citation statements)
references
References 36 publications
0
16
0
Order By: Relevance
“…Another series using the same antibody found positive cytoplasmic staining for WT1 in 68% of TNBC . High WT1 mRNA expression levels have been associated with poor prognosis in breast cancer, and show a correlation with ER‐negative, basal‐like and HER2 molecular subtypes …”
Section: Discussionmentioning
confidence: 93%
“…Another series using the same antibody found positive cytoplasmic staining for WT1 in 68% of TNBC . High WT1 mRNA expression levels have been associated with poor prognosis in breast cancer, and show a correlation with ER‐negative, basal‐like and HER2 molecular subtypes …”
Section: Discussionmentioning
confidence: 93%
“…A total of 29 studies 9 11 12 13 14 15 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 with 32 datasets and 4090 patients assessing the relationship between WT1 expression and prognosis of solid tumors were initially identified ( Figure 1 ), and the details of selected studies are shown in Table 1 . Twenty-one datasets evaluated carcinoma (9 for ovarian cancer, 5 for breast cancer, 3 for non-small-cell lung cancer [NSCLC], 2 for endometrial cancer, 1 for colorectal cancer and 1 for hepatocellular carcinoma) and 11 datasets evaluated non-carcinoma (2 for soft tissue sarcoma).…”
Section: Resultsmentioning
confidence: 99%
“…It has been shown that WT1 was overexpressed in a number of cancer cells, and more importantly, knockdown of WT1 by shRNA could induce mitochondrial damage and then inhibit malignant cell growth 10 . In addition to its prognostic role in a variety cancer types 11 12 13 14 15 , WT1 was also recognized as a promising target for immunotherapy based on its unique features 16 17 , and preliminary results from clinical vaccine trials revealed WT1's untapped potential to induce cancer immunity with minimal side effects 18 19 20 .…”
mentioning
confidence: 99%
“…In addition, WT1 promoted ovarian cancer invasion (38,39). In breast cancer, WT1 expression level was associated with basal-like and receptor tyrosine-protein kinase erbB-2 molecular subtypes and poor prognosis (40). In addition, it was demonstrated to enhance growth and inhibit apoptosis of breast cancer cells (41,42).…”
Section: Discussionmentioning
confidence: 99%